- Advanced search
- Immuno Portal
- Malaria Portal
Molecular properties generated using the CDK
|Compound 13r shows little selectivity across the members of the Type I receptor serine/threonine kinases family, which contains the bone morphogenetic protein receptors, and also inhibits transforming growth factor, beta receptor II (TGFBR2, a Type II receptor serine/threonine kinase) with IC50 of 15nM .
We have tagged ALK1/ACVRL1 as primary target for compound 13r based only on the fact that this is the first member of the protein family, with several members being equally sensitive to compound 13r inhibition.
|Selectivity at catalytic receptors|
|Key to terms and symbols||Click column headers to sort|